Startups
Transposon Therapeutics
Develops oral medicines targeting abnormal retrotransposon activity and other pathways involved in neurodegenerative and aging-related diseases. Its lead investigational drug, TPN-101, inhibits LINE-1 reverse transcriptase and is being developed for ALS, progressive supranuclear palsy and Alzheimer’s disease. The pipeline also includes nucleoside analogs and PKR inhibitors.
Team
 Adam BoxerClinical Advisory Board Member |
Andrew SatlinChief Medical Officer |
Bess FrostScientific Advisory Board Member |
 Bill HarringtonBoard Director |
Brent AhrensBoard Director |
 BT SlingsbyBoard Director |
Daniel HétuBoard Director |
Dennis PodlesakCEO and Chair |
Eckard WeberChief Innovation Officer and Board Director |
Ethan GeierSenior Director, Research and Development |
George ChurchScientific Advisory Board Member |
Jay SotoHead, Clinical Operations |
John PacificoBoard Director |
John RavitsClinical Advisory Board Member |
John SedivyScientific Advisory Board Chair |
Josh DubnauScientific Advisory Board Member |
Kathy BurnsScientific Advisory Board Member |
Keith KatkinBoard Director |
Lynne RollinsChief Financial Officer |
Mark MugerditchianVP Manufacturing |
 Merit CudkowiczClinical Advisory Board Member |
Michael CordingleyChief Scientific Officer |
Molly Gale HammellScientific Advisory Board Member |
Murali DoraiswamyClinical Advisory Board Chair |
Priya JambhekarHead, Regulatory |
Rick OrrHead, BD and Corp Counsel |
Rusty GageScientific Advisory Board Member |
Walter BeeSVP Preclinical and Biomarker Development |
Yanick CrowClinical Advisory Board Member |